Study Evaluating Venlafaxine ER in Patients With Panic Disorder

A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00044772

Enrollment

653

Registered

2002-09-06

Start date

2001-11-30

Completion date

2003-04-30

Last updated

2009-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Keywords

Panic, Disorder

Brief summary

The primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (ER) capsules in the treatment of outpatients with panic disorder (PD) in comparison to those of placebo.

Interventions

DRUGVenlafaxine ER

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Meet DSM-IV criteria for PD (with or without agoraphobia) for at least 3 months before study day 1 * Have sufficient symptoms to require anxiolytic drug therapy * Have a score ≥4 on the Clinical Global Impressions Scale (CGI) severity of illness item at screening and baseline

Exclusion criteria

* Known hypersensitivity to venlafaxine (IR or ER), related compounds, or paroxetine * History or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension) * Clinically important abnormality on screening physical examination, vital signs, electrocardiogram (ECG), laboratory tests or urine drug screen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026